Literature DB >> 23612917

[The chronic critically ill patient from the cardiologist's perspective].

U Janssens1, S Reith.   

Abstract

In recent years the prognosis and survival of chronic and acute heart failure (HF) patients has been steadily improving; however, many patients develop advanced chronic HF which is characterized by worsening of symptoms, unplanned hospital admission due to acute decompensation, development of complications, such as life-threatening arrhythmia and shorter life span. Optimal medical therapy is supplemented by interventional cardiology, cardiovascular implantable electronic devices (CIEDs), minimally invasive valve replacement or repair, circulatory mechanical support and heart transplantation. Medical indications and informed consent are essential prerequisites for successfully implementing treatment goals. For patients who are incapable of decisions a legally defined surrogate decision-maker has the same right to refuse or request the withdrawal of treatment as the patient would have if the patient had decision-making capability. As the use of circulatory mechanical support becomes increasingly more prevalent, ethical issues are likely to arise at an increasing rate, as will social and legal ramifications. The concept of turning off an implanted device as death nears is challenging because of ethical and technical concerns. The same holds true for CIEDs. A palliative care approach is applicable to heart failure patients and is particularly relevant to those with advanced disease. Palliative care should be integrated as part of a team approach to comprehensive HF care and should not be reserved for those who are expected to die within days or weeks.

Entities:  

Mesh:

Year:  2013        PMID: 23612917     DOI: 10.1007/s00063-012-0193-z

Source DB:  PubMed          Journal:  Med Klin Intensivmed Notfmed        ISSN: 2193-6218            Impact factor:   0.840


  43 in total

1.  Current controversies in critical care ethics: not just end of life.

Authors:  Michael A DeVita; Jeffrey Groeger; Robert Truog
Journal:  Crit Care Med       Date:  2003-05       Impact factor: 7.598

2.  Illness trajectories and palliative care.

Authors:  Scott A Murray; Marilyn Kendall; Kirsty Boyd; Aziz Sheikh
Journal:  BMJ       Date:  2005-04-30

3.  Should implantable cardioverter-defibrillators and permanent pacemakers in patients with terminal illness be deactivated? Deactivating implantable cardioverter-defibrillators and permanent pacemakers in patients with terminal illness. An ethical distinction.

Authors:  G Neal Kay; Gregory T Bittner
Journal:  Circ Arrhythm Electrophysiol       Date:  2009-06

4.  2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management.

Authors:  Jean-Claude Daubert; Leslie Saxon; Philip B Adamson; Angelo Auricchio; Ronald D Berger; John F Beshai; Ole Breithard; Michele Brignole; John Cleland; David B DeLurgio; Kenneth Dickstein; Derek V Exner; Michael Gold; Richard A Grimm; David L Hayes; Carsten Israel; Christophe Leclercq; Cecilia Linde; JoAnn Lindenfeld; Bela Merkely; Lluis Mont; Francis Murgatroyd; Frits Prinzen; Samir F Saba; Jerold S Shinbane; Jagmeet Singh; Anthony S Tang; Panos E Vardas; Bruce L Wilkoff; Jose Luis Zamorano; Inder Anand; Carina Blomström-Lundqvist; John P Boehmer; Hugh Calkins; Serge Cazeau; Victoria Delgado; N A Mark Estes; David Haines; Fred Kusumoto; Paco Leyva; Frank Ruschitzka; Lynne Warner Stevenson; Christian Tobias Torp-Pedersen
Journal:  Europace       Date:  2012-09       Impact factor: 5.214

5.  Pre-operative and post-operative risk factors associated with neurologic complications in patients with advanced heart failure supported by a left ventricular assist device.

Authors:  Tomoko S Kato; P Christian Schulze; Jonathan Yang; Ernest Chan; Khurram Shahzad; Hiroo Takayama; Nir Uriel; Ulrich Jorde; Maryjane Farr; Yoshifumi Naka; Donna Mancini
Journal:  J Heart Lung Transplant       Date:  2011-10-08       Impact factor: 10.247

6.  The ethics of mechanical support: the need for new guidelines.

Authors:  John W C Entwistle; Robert M Sade; Ralph J Petrucci
Journal:  Ann Thorac Surg       Date:  2011-12       Impact factor: 4.330

Review 7.  Contemporary management and research directions in advanced heart failure: where are we going?

Authors:  Abdallah Kamouh; Gary S Francis
Journal:  Congest Heart Fail       Date:  2011-07-21

8.  Second INTERMACS annual report: more than 1,000 primary left ventricular assist device implants.

Authors:  James K Kirklin; David C Naftel; Robert L Kormos; Lynne W Stevenson; Francis D Pagani; Marissa A Miller; Karen L Ulisney; J Timothy Baldwin; James B Young
Journal:  J Heart Lung Transplant       Date:  2010-01       Impact factor: 10.247

9.  Use of a continuous-flow device in patients awaiting heart transplantation.

Authors:  Leslie W Miller; Francis D Pagani; Stuart D Russell; Ranjit John; Andrew J Boyle; Keith D Aaronson; John V Conte; Yoshifumi Naka; Donna Mancini; Reynolds M Delgado; Thomas E MacGillivray; David J Farrar; O H Frazier
Journal:  N Engl J Med       Date:  2007-08-30       Impact factor: 91.245

10.  Advanced heart failure treated with continuous-flow left ventricular assist device.

Authors:  Mark S Slaughter; Joseph G Rogers; Carmelo A Milano; Stuart D Russell; John V Conte; David Feldman; Benjamin Sun; Antone J Tatooles; Reynolds M Delgado; James W Long; Thomas C Wozniak; Waqas Ghumman; David J Farrar; O Howard Frazier
Journal:  N Engl J Med       Date:  2009-11-17       Impact factor: 91.245

View more
  2 in total

1.  [Dying with/despite a pacemaker].

Authors:  S Reith; U Janssens
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-01-04       Impact factor: 0.840

2.  Referral Criteria to Palliative Care for Patients With Heart Failure: A Systematic Review.

Authors:  Yuchieh Kathryn Chang; Holland Kaplan; Yimin Geng; Li Mo; Jennifer Philip; Anna Collins; Larry A Allen; John A McClung; Martin A Denvir; David Hui
Journal:  Circ Heart Fail       Date:  2020-09-09       Impact factor: 8.790

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.